This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.



Status:Terminated
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 65
Updated:4/21/2016
Start Date:July 2009
End Date:April 2014

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Substance P Neuropeptide Levels in Saliva, Serum and Cerebrospinal Fluid in Patients With Spinal Disease: A Pilot Study

The objective of this pilot study is to determine if degenerative spinal disorders such as
acute radiculopathy, myelopathy, stenosis, or disc and facet disease cause detectable
alterations in Substance P levels in saliva, serum and cerebrospinal fluid. If this pilot
study shows a correlation between Substance P levels and pain associated with degenerative
spinal disorders, then a larger study will be initiated to determine the feasibility of
using Substance P levels in the diagnosis and treatment of degenerative spinal disease.


Inclusion Criteria:

- Undergoing spinal surgery for medically refractory spinal radiculopathy,

- myelopathy or neurogenic claudication based on either history, physical examination
or radiologic studies demonstrating neural compression or degenerative disc disease.

- Undergoing surgery for medically refractory axial spinal pain.

Exclusion Criteria:

- Previous spinal procedures or operations,

- radicular pain,

- history of fibromyalgia,

- chronic pain,

- rheumatoid arthritis,

- autoimmune disorders,

- HIV,

- PTSD,

- Major Depressive Disorder,

- migraine headaches or active rhinosinusitis,

- nicotine intake
We found this trial at
1
site
Carolina NeuroSurgery & Spine Associates
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials